|
1
|
Ramalingam SS, Owonikoko TK and Khuri FR:
Lung cancer: New biological insights and recent therapeutic
advances. CA Cancer J Clin. 61:91–112. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ladanyi M and Pao W: Lung adenocarcinoma:
Guiding EGFR-targeted therapy and beyond. Mod Pathol. 21(Suppl 2):
S16–S22. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Martin J, Ginsberg RJ, Venkatraman ES,
Bains MS, Downey RJ, Korst RJ, Kris MG and Rusch VW: Long-term
results of combined-modality therapy in resectable non-small-cell
lung cancer. J Clin Oncol. 20:1989–1995. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Strauss LT, Herndon J, Chang J, Parker WY,
Levy DA, Bowens SB, Zane SB and Berg CJ; CDC: Abortion
surveillance-United States, 2001. MMWR Surveill Summ. 53:1–32.
2004.PubMed/NCBI
|
|
5
|
Spiro SG and Silvestri GA: One hundred
years of lung cancer. Am J Respir Crit Care Med. 172:523–529. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dwamena BA, Sonnad SS, Angobaldo JO and
Wahl RL: Metastases from non-small cell lung cancer: Mediastinal
staging in the 1990s-meta-analytic comparison of PET and CT.
Radiology. 213:530–536. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cerfolio RJ, Ojha B, Bryant AS, Raghuveer
V, Mountz JM and Bartolucci AA: The accuracy of integrated PET-CT
compared with dedicated PET alone for the staging of patients with
nonsmall cell lung cancer. Ann Thorac Surg. 78:1017–1023. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mac MMP, Hicks RJ, Matthews JP, McKenzie
A, Rischin D, Salminen EK and Ball DL: Positron emission tomography
is superior to computed tomography scanning for response-assessment
after radical radiotherapy or chemoradiotherapy in patients with
non-small-cell lung cancer. J Clin Oncol. 21:1285–1292. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Novello S, Vavala T, Levra MG, Solitro F,
Pelosi E, Veltri A and Scagliotti GV: Early response to
chemotherapy in patients with non-small-cell lung cancer assessed
by [18F]-fluoro-deoxy-D-glucose positron emission tomography and
computed tomography. Clin Lung Cancer. 14:230–237. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Edge S, Byrd DR, Compton CC, Fritz AG,
Greene FL and Trotti A: American Joint Committee on Cancer (AJCC)
From the AJCC Cancer Staging Manual. 7th edition. Springer-Verlag;
New York, NY; 2010
|
|
11
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the eastern cooperative oncology group. Am J Clin
Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Birim O, Kappetein AP, van Klaveren RJ and
Bogers AJ: Prognostic factors in non-small cell lung cancer
surgery. Eur J Surg Oncol. 32:12–23. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Weber WA, Petersen V, Schmidt B,
Tyndale-Hines L, Link T, Peschel C and Schwaiger M: Positron
emission tomography in non-small-cell lung cancer: Prediction of
response to chemotherapy by quantitative assessment of glucose use.
J Clin Oncol. 21:2651–2657. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hoekstra CJ, Stroobants SG, Smit EF,
Vansteenkiste J, van Tinteren H, Postmus PE, Golding RP, Biesma B,
Schramel FJ, van Zandwijk N, et al: Prognostic relevance of
response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron
emission tomography in patients with locally advanced
non-small-cell lung cancer. J Clin Oncol. 23:8362–8370. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shiraishi K, Nomori H, Ohba Y, Kaji M,
Mori T, Shibata H, Oya N and Sasaki J: Repeat FDG-PET for
predicting pathological tumor response and prognosis after
neoadjuvant treatment in nonsmall cell lung cancer: Comparison with
computed tomography. Ann Thorac Cardiovasc Surg. 16:394–400.
2010.PubMed/NCBI
|
|
17
|
Yamamoto Y, Nishiyama Y, Monden T,
Sasakawa Y, Ohkawa M, Gotoh M, Kameyama K and Haba R: Correlation
of FDG-PET findings with histopathology in the assessment of
response to induction chemoradiotherapy in non-small cell lung
cancer. Eur J Nucl Med Mol Imaging. 33:140–147. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Eschmann SM, Friedel G, Paulsen F, Reimold
M, Hehr T, Budach W, Dittmann H, Langen HJ and Bares R: Repeat
18F-FDG PET for monitoring neoadjuvant chemotherapy in patients
with stage III non-small cell lung cancer. Lung Cancer. 55:165–171.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mac MMP, Hicks RJ, Matthews JP, Wirth A,
Rischin D and Ball DL: Metabolic (FDG-PET) response after radical
radiotherapy/chemoradiotherapy for non-small cell lung cancer
correlates with patterns of failure. Lung Cancer. 49:95–108. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Avril NE and Weber WA: Monitoring response
to treatment in patients utilizing PET. Radiol Clin North Am.
43:189–204. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Machtay M, Duan F, Siegel BA, Snyder BS,
Gorelick JJ, Reddin JS, Munden R, Johnson DW, Wilf LH, DeNittis A,
et al: Prediction of survival by [18F]fluorodeoxyglucose positron
emission tomography in patients with locally advanced
non-small-cell lung cancer undergoing definitive chemoradiation
therapy: Results of the ACRIN 6668/RTOG 0235 trial. J Clin Oncol.
31:3823–3830. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xu X, Yu J, Sun X, Yang G, Li K, Fu Z, Han
A and Zheng J: The prognostic value of 18F-fluorodeoxyglucose
uptake by using serial positron emission tomography and computed
tomography in patients with stage III nonsmall cell lung cancer. Am
J Clin Oncol. 31:470–475. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bollineni VR, Widder J, Pruim J,
Langendijk JA and Wiegman EM: Residual 18F-FDG-PET
uptake 12 weeks after stereotactic ablative radiotherapy for stage
I non-small-cell lung cancer predicts local control. Int J Radiat
Oncol Biol Phys. 83:e551–e555. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lopez Guerra JL, Gladish G, Komaki R,
Gomez D, Zhuang Y and Liao Z: Large decreases in standardized
uptake values after definitive radiation are associated with better
survival of patients with locally advanced non-small cell lung
cancer. J Nucl Med. 53:225–233. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Na F, Wang J, Li C, Deng L, Xue J and Lu
Y: Primary tumor standardized uptake value measured on
F18-Fluorodeoxyglucose positron emission tomography is of
prediction value for survival and local control in non-small-cell
lung cancer receiving radiotherapy: Meta-analysis. J Thorac Oncol.
9:834–842. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Satoh Y, Onishi H, Nambu A and Araki T:
Volume-based parameters measured by using FDG PET/CT in patients
with stage I NSCLC treated with stereotactic body radiation
therapy: Prognostic value. Radiology. 270:275–281. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lee P, Weerasuriya DK, Lavori PW, Quon A,
Hara W, Maxim PG, Le QT, Wakelee HA, Donington JS, Graves EE and
Loo BW Jr: Metabolic tumor burden predicts for disease progression
and death in lung cancer. Int J Radiat Oncol Biol Phys. 69:328–333.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Casali C, Cucca M, Rossi G, Barbieri F,
Iacuzio L, Bagni B and Uliano M: The variation of prognostic
significance of Maximum Standardized Uptake Value of
[18F]-fluoro-2-deoxy-glucose positron emission tomography in
different histological subtypes and pathological stages of
surgically resected non-small cell lung carcinoma. Lung Cancer.
69:187–193. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Vesselle H, Salskov A, Turcotte E, Wiens
L, Schmidt R, Jordan CD, Vallières E and Wood DE: Relationship
between non-small cell lung cancer FDG uptake at PET, tumor
histology, and Ki-67 proliferation index. J Thorac Oncol.
3:971–978. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ikushima H, Dong L, Erasmus J, Allen P,
McAleer MF, Zhuang Y, Sasaki R and Komaki R: Predictive value of
18F-fluorodeoxyglucose uptake by positron emission tomography for
non-small cell lung cancer patients treated with radical
radiotherapy. J Radiat Res. 51:465–471. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mery CM, Pappas AN, Burt BM, Bueno R,
Linden PA, Sugarbaker DJ and Jaklitsch MT: Diameter of non-small
cell lung cancer correlates with long-term survival: Implications
for T stage. Chest. 128:3255–3260. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Takeda S, Fukai S, Komatsu H, Nemoto E,
Nakamura K and Murakami M; Japanese National Chest Hospital Study
Group: Impact of large tumor size on survival after resection of
pathologically node negative (pN0) non-small cell lung cancer. Ann
Thorac Surg. 79:1142–1146. 2005. View Article : Google Scholar : PubMed/NCBI
|
